ADMA BIOLOGICS, INC.
ADMADrugs in Pipeline
3
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
RI-002
Primary Immune Deficiency Disorder
Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%]
Primary Immune Deficiency Disorders (PIDD)
RI-001
Upper Respiratory Tract Infection
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
RI-002 | Phase 3 | Primary Immune Deficiency Disorder | - | - |
Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%] | Phase 3 | Primary Immune Deficiency Disorders (PIDD) | - | - |
RI-001 | Phase 2 | Upper Respiratory Tract Infection | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in ADMA BIOLOGICS, INC.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in ADMA BIOLOGICS, INC.'s (ADMA) pipeline across Phase 3, Phase 2. Its lead program is RI-002 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is ADMA BIOLOGICS, INC.'s next FDA catalyst?→
ADMA BIOLOGICS, INC.'s (ADMA) next tracked catalyst is a Earnings expected November 4, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ADMA biotech catalysts?→
Add ADMA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow ADMA BIOLOGICS, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.